Aquaretic Effect of Lixivaptan, an Oral, Non-Peptide, Selective V2 Receptor Vasopressin Antagonist, in New York Heart Association Functional Class II and III Chronic Heart Failure Patients
William T. Abraham, MD*,*,
Alireza A. Shamshirsaz, MD ,
Kim McFann, MD,
Ron M. Oren, MD and
Robert W. Schrier, MD
* The Ohio State University Heart Center, Columbus, Ohio
University of Colorado, Health Sciences Center, Denver, Colorado
University of Iowa Hospitals and Clinics, Iowa City, Iowa
View larger version (32K):
[in a new window]
|
Figure 1 Urine flow rates for the groups randomized to lixivaptan or placebo. The top panel presents data after single-blind placebo administration (baseline). The bottom panel depicts results after administration of double-blind study medication, consisting of either placebo or one of six doses of lixivaptan as indicated. At 1 h, urine flow was significantly increased at the higher doses of lixivaptan. At 2 h, urine flow was significantly increased at all doses >10 mg. See text for specific p values.
|
|
View larger version (27K):
[in a new window]
|
Figure 2 Effect of V2 antagonism on solute-free water excretion. The top panel presents data after single-blind placebo administration (baseline). The bottom panel depicts results after administration of double-blind study medication, consisting of either placebo or one of six doses of lixivaptan as indicated. Lixivaptan dramatically increased free water excretion within the first 2 h, after study drug administration. See text for specific p values.
|
|
|
